First Trust Advisors L.P. (“First Trust”), a leading provider of investment products and services that help financial advisors meet the financial needs and objectives of their clients, is pleased to mark the fifth anniversary of the First Trust NYSE Arca Biotechnology Index Fund (NYSE Arca: FBT). This exchange-traded fund seeks investment results that correspond generally to the price and yield (before the fund’s fees and expenses) of the NYSE Arca Biotechnology Index SM.
Since its inception on June 19, 2006, FBT has delivered an average annual total return of 17.16% through June 30, 2011. The fund has outperformed its benchmark, the NASDAQ Biotech Index, by 7.79% per year, and the broad market S&P 500 Index by 13.73% per year during that time. FBT, which had $550 million in assets as of June 30, 2011, is the top-performing exchange-traded fund (ETF) in the Morningstar health category for the past five years ended June, 30, 2011 (out of 13 ETFs) and has received a 5-Star Overall Morningstar Rating TM.*
|Quarter End Performance (as of 6/30/11)||Quarter||YTD||1 Yr.||3 Yr.||5 Yr.||10 Yr.||
|Fund Performance 1|
|After Tax Held||6.43||%||12.21||%||41.92||%||24.81||%||16.27||%||N/A||17.07||%|
|After Tax Sold||4.18||%||7.94||%||27.25||%||21.70||%||14.38||%||N/A||15.10||%|
|NYSE Arca Biotechnology Index SM2||6.63||%||12.56||%||42.77||%||25.57||%||17.08||%||9.09||%||17.89||%|
|NASDAQ Biotech Index||6.53||%||14.34||%||39.79||%||12.29||%||8.71||%||1.08||%||9.37||%|
|S&P Composite 1500 Health Care Index||7.26||%||14.19||%||29.54||%||8.08||%||5.78||%||3.40||%||5.95||%|
|S&P 500 Index||0.10||%||6.02||%||30.69||%||3.34||%||2.94||%||2.72||%||3.43||%|
Performance data quoted represents past performance. Past performance is not a guarantee of future results and current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and shares when sold or redeemed, may be worth more or less than their original cost. You can obtain performance information which is current through the most recent month-end by visiting www.ftportfolios.com .
“FBT is a pure-play biotech fund, comprised of 20 stocks, that mirrors the tremendous growth of the biotechnology industry,” said Ryan Issakainen, Senior Vice President and Exchange-Traded Fund Strategist for First Trust. “Our fund provides equally-weighted exposure to each of its holdings, rather than the traditional market-cap weighted approach followed by many ETFs. This has enabled FBT to benefit from positive news coming out of small- and mid-sized biotech companies, such as breakthrough treatments and M&A announcements. Because the performance of biotech stocks is significantly impacted by these sorts of company-specific events, we believe it is important to give equal exposure to companies in the biotech industry, without diluting performance with too many holdings,” Issakainen concluded.